Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy - PubMed

Affiliations

• PMID: 16446309
• DOI: 10.1093/hmg/ddl003

Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy

Lina S Correa-Cerro et al. Hum Mol Genet. 2006.

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is a genetic syndrome caused by mutations in the 3beta-hydroxysterol Delta(7)-reductase gene (DHCR7). SLOS patients have decreased cholesterol and increased 7-dehydrocholesterol (7-DHC) levels. Dietary cholesterol supplementation improves systemic biochemical abnormalities; however, because of the blood-brain barrier, the central nervous system (CNS) is not treated. Simvastatin therapy has been proposed as a means to treat the CNS. Mice homozygous for a null disruption of Dhcr7, Dhcr7(Delta3-5/Delta3-5), die soon after birth, thus they cannot be used to study postnatal development or therapy. To circumvent this problem, we produced a hypomorphic SLOS mouse model by introducing a mutation corresponding to DHCR7(T93M). Both Dhcr7(T93M/T93M) and Dhcr7(Delta3-5/T93M) mice are viable. Phenotypic findings in Dhcr7(T93M/Delta3-5) mice include CNS ventricular dilatation and two to three syndactyly. Biochemically, both Dhcr7(T93M/T93M) and Dhcr7(T93M/Delta3-5) mice have elevated tissue 7-DHC levels; however, the biochemical defect improved with age. This has not been observed in human patients, and is due to elevated Dhcr7 expression in mouse tissues. Dietary cholesterol therapy improved sterol profiles in peripheral, but not CNS tissues. However, treatment of Dhcr7(T93M/Delta3-5) mice with simvastatin decreased 7-DHC levels in both peripheral and brain tissues. Expression of Dhcr7 increased in Dhcr7(T93M/Delta3-5) tissues after simvastatin therapy, consistent with the hypothesis that simvastatin therapy improves the biochemical phenotype by increasing the expression of a Dhcr7 allele with residual enzymatic activity. We conclude that simvastatin treatment is efficacious in improving the SLOS-associated sterol abnormality found in the brain, and thus has the potential to be an effective therapeutic intervention for behavioral and learning problems associated with SLOS.

Similar articles

• Residual cholesterol synthesis and simvastatin induction of cholesterol synthesis in Smith-Lemli-Opitz syndrome fibroblasts.

  Wassif CA, Krakowiak PA, Wright BS, Gewandter JS, Sterner AL, Javitt N, Yergey AL, Porter FD. Wassif CA, et al. Mol Genet Metab. 2005 Jun;85(2):96-107. doi: 10.1016/j.ymgme.2004.12.009. Epub 2005 Feb 5. Mol Genet Metab. 2005. PMID: 15896653

• Analysis by liquid chromatography-mass spectrometry of sterols and oxysterols in brain of the newborn Dhcr7(Δ3-5/T93M) mouse: a model of Smith-Lemli-Opitz syndrome.

  Meljon A, Watson GL, Wang Y, Shackleton CH, Griffiths WJ. Meljon A, et al. Biochem Pharmacol. 2013 Jul 1;86(1):43-55. doi: 10.1016/j.bcp.2013.03.003. Epub 2013 Mar 13. Biochem Pharmacol. 2013. PMID: 23500538 Free PMC article.

• 3beta-hydroxysterol Delta7-reductase and the Smith-Lemli-Opitz syndrome.

  Correa-Cerro LS, Porter FD. Correa-Cerro LS, et al. Mol Genet Metab. 2005 Feb;84(2):112-26. doi: 10.1016/j.ymgme.2004.09.017. Epub 2004 Dec 19. Mol Genet Metab. 2005. PMID: 15670717 Review.

• A placebo-controlled trial of simvastatin therapy in Smith-Lemli-Opitz syndrome.

  Wassif CA, Kratz L, Sparks SE, Wheeler C, Bianconi S, Gropman A, Calis KA, Kelley RI, Tierney E, Porter FD. Wassif CA, et al. Genet Med. 2017 Mar;19(3):297-305. doi: 10.1038/gim.2016.102. Epub 2016 Aug 11. Genet Med. 2017. PMID: 27513191 Free PMC article. Clinical Trial.

• Recent insights into the Smith-Lemli-Opitz syndrome.

  Yu H, Patel SB. Yu H, et al. Clin Genet. 2005 Nov;68(5):383-91. doi: 10.1111/j.1399-0004.2005.00515.x. Clin Genet. 2005. PMID: 16207203 Free PMC article. Review.

Cited by

• Statins and pregnancy: between supposed risks and theoretical benefits.

  Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Lecarpentier E, et al. Drugs. 2012 Apr 16;72(6):773-88. doi: 10.2165/11632010-000000000-00000. Drugs. 2012. PMID: 22480340 Review.

• Steroid production and excretion by the pregnant mouse, particularly in relation to pregnancies with fetuses deficient in Delta7-sterol reductase (Dhcr7), the enzyme associated with Smith-Lemli-Opitz syndrome.

  Matabosch X, Rahman M, Hughes B, Patel SB, Watson G, Shackleton C. Matabosch X, et al. J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):61-70. doi: 10.1016/j.jsbmb.2009.04.011. Epub 2009 May 3. J Steroid Biochem Mol Biol. 2009. PMID: 19406241 Free PMC article.

• Oxidative stress, serotonergic changes and decreased ultrasonic vocalizations in a mouse model of Smith-Lemli-Opitz syndrome.

  Sharif NF, Korade Z, Porter NA, Harrison FE. Sharif NF, et al. Genes Brain Behav. 2017 Jul;16(6):619-626. doi: 10.1111/gbb.12376. Epub 2017 Mar 15. Genes Brain Behav. 2017. PMID: 28220990 Free PMC article.

• Cholesterol biosynthesis from birth to adulthood in a mouse model for 7-dehydrosterol reductase deficiency (Smith-Lemli-Opitz syndrome).

  Marcos J, Shackleton CH, Buddhikot MM, Porter FD, Watson GL. Marcos J, et al. Steroids. 2007 Oct;72(11-12):802-8. doi: 10.1016/j.steroids.2007.07.002. Epub 2007 Jul 13. Steroids. 2007. PMID: 17714750 Free PMC article.

• Hair and skin sterols in normal mice and those with deficient dehydrosterol reductase (DHCR7), the enzyme associated with Smith-Lemli-Opitz syndrome.

  Serra M, Matabosch X, Ying L, Watson G, Shackleton C. Serra M, et al. J Steroid Biochem Mol Biol. 2010 Nov;122(5):318-25. doi: 10.1016/j.jsbmb.2010.08.006. Epub 2010 Sep 6. J Steroid Biochem Mol Biol. 2010. PMID: 20804844 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Miscellaneous

  • NCI CPTAC Assay Portal